Topics

Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

02:46 EDT 28 Oct 2019 | FinanzNachrichten

Regulatory News: Advicenne (Paris:ADVIC) (BSE:ADVIC) (Euronext: ADVIC FR0013296746), a specialty pharmaceutical company focused on the development and commercialization of therapeutic products for...

Original Article: Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress

NEXT ARTICLE

More From BioPortfolio on "Advicenne Presented Additional Efficacy Data on ADV7103 in the Treatment of dRTA at International Pediatric Nephrology Association Congress"

Quick Search